{"transactions":[{"id":747882,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T20:32:49.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":90000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001612312-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000161231226000002/primarydocument.xml","form_type":"4"}},{"id":1117851,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:40:28.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":80000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-25-004646","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218025004646/primarydocument.xml","form_type":"4"}},{"id":1454565,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T20:08:55.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."}],"balance_after":65000,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-24-005715","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218024005715/primarydocument.xml","form_type":"4/A","original_submission_date":"2024-06-07"}},{"id":1486716,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:21:26.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":54278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":54278,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":54278},"source":{"system":"sec-edgar","filing":"0001562180-24-004838","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218024004838/primarydocument.xml","form_type":"4"}},{"id":1860467,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:34:16.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023."}],"balance_after":65000,"derivative":{"exercise_price":6.7,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-23-005030","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218023005030/primarydocument.xml","form_type":"4"}},{"id":2007579,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-17T22:17:55.000Z","date":"2021-02-03","kind":"purchase","acquired":true,"shares":20000,"price":25,"value":500000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001562180-23-001518","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218023001518/primarydocument.xml","form_type":"4"}},{"id":2206976,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-15T21:05:45.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award made pursuant to Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":7.02,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001728117-22-000071","document":"wf-form4_165791912081771.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000172811722000071/wf-form4_165791912081771.xml","form_type":"4"}},{"id":2239114,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T22:38:22.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022."}],"balance_after":65000,"derivative":{"exercise_price":4.95,"expiration_date":"2032-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-22-004945","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156218022004945/primarydocument.xml","form_type":"4"}},{"id":2673954,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T01:41:52.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":23500,"derivative":{"exercise_price":8.97,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001728117-21-000068","document":"wf-form4_162337569513720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000172811721000068/wf-form4_162337569513720.xml","form_type":"4"}},{"id":2850132,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T23:59:54.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":11795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in full on February 3, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."}],"balance_after":11795,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":11795},"source":{"system":"sec-edgar","filing":"0000899243-21-007194","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000089924321007194/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-05"}},{"id":2876632,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T22:18:59.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on February 3, 2022."}],"balance_after":7000,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-21-005076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000089924321005076/doc4.xml","form_type":"4"}},{"id":3105460,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:52:31.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":23500,"derivative":{"exercise_price":12.1,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001209191-20-037635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000120919120037635/doc4.xml","form_type":"4"}},{"id":3494266,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T22:30:09.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":23500,"derivative":{"exercise_price":19.54,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001209191-19-036209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000120919119036209/doc4.xml","form_type":"4"}},{"id":3653794,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":128000,"price":235,"value":30080000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":139.77,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":128000},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653793,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":235,"value":70500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":84.88,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653792,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":235,"value":23500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":43.56,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653791,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":209000,"price":235,"value":49115000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.27,"expiration_date":"2026-12-05","underlying":"Common Stock","underlying_shares":209000},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653790,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":142000,"price":235,"value":33370000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":31.69,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":142000},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653789,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":318514,"price":235,"value":74850790.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":318514},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653788,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":64471,"price":235,"value":15150685.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":64471},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653787,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":27459,"price":235,"value":6452865.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.184,"expiration_date":"2023-11-14","underlying":"Common Stock","underlying_shares":27459},"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653786,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":235,"value":7050000.0,"ownership":{"direct":false,"nature":"By Joshua H. Bilenker,ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3653785,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-15T14:06:19.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":162707,"price":235,"value":38236145.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-004566","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919004566/doc1.xml","form_type":"4"}},{"id":3693070,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-01-17T13:06:55.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":7500,"price":1.184,"value":8880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amended Form 4 is being filed solely to correct the reporting person's ending balance by subtracting the additional 1,700 shares of the Issuer's common stock (the \"Additional Shares\") that were added inadvertently to the total number of shares held directly by the reporting person. The Additional Shares were included in all the subsequent directly held transactions in the Form 4 filed on July 11, 2018 and the five Forms 4 filed thereafter. As of January 17, 2019, the reporting person directly holds a total number of 162,707 shares of the Issuer's common stock."}],"balance_after":141207,"source":{"system":"sec-edgar","filing":"0001567619-19-001261","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919001261/doc1.xml","form_type":"4/A","original_submission_date":"2018-07-11"}},{"id":3713341,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-02T22:03:24.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":128000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 1/48th of the total number of shares on February 2, 2019, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date."}],"balance_after":128000,"derivative":{"exercise_price":139.77,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":128000},"source":{"system":"sec-edgar","filing":"0001567619-19-000101","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761919000101/doc1.xml","form_type":"4"}},{"id":3734049,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":318514,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734048,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":328514,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734047,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":100,"price":140.61,"value":14061.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":164407,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734046,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":1200,"price":140.15,"value":168180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.59 to $140.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164507,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734045,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":1100,"price":139.05,"value":152955.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.53 to $139.40 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165707,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734044,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":2407,"price":137.63,"value":331275.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.32 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":166807,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734043,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":3393,"price":136.79,"value":464128.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.31 to $137.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169214,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734042,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":1153,"price":135.76,"value":156531.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.30 to $136.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":172607,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734041,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":647,"price":134.63,"value":87105.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.28 to $135.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":173760,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734040,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-11","kind":"exercise","acquired":true,"shares":10000,"price":13.67,"value":136700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":174407,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734039,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":100,"price":137.39,"value":13739.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":164407,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734038,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":400,"price":136.48,"value":54592.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164507,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734037,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":2377,"price":135.04,"value":320990.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.91 to $135.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164907,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734036,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":2049,"price":134.31,"value":275201.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.91 to $134.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":167284,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734035,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":2104,"price":133,"value":279832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.56 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169333,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734034,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":2001,"price":132.09,"value":264312.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.48 to $132.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":171437,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734033,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":969,"price":130.58,"value":126532.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.14 to $131.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":173438,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3734032,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-12T22:12:49.000Z","date":"2018-12-10","kind":"exercise","acquired":true,"shares":10000,"price":13.67,"value":136700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":174407,"source":{"system":"sec-edgar","filing":"0001567619-18-007783","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007783/doc1.xml","form_type":"4"}},{"id":3750408,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F21","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":338514,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750407,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":false,"shares":1486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F21","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":348514,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":1486},"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750406,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":false,"shares":8514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":64471,"derivative":{"exercise_price":3.684,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":8514},"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750405,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":false,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F19","text":"The options have fully vested and are immediately exercisable."}],"balance_after":27459,"derivative":{"exercise_price":1.184,"expiration_date":"2023-11-14","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750404,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":200,"price":151.56,"value":30312.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":164407,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750403,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":400,"price":149.25,"value":59700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.99 to $149.71 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164607,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750402,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":250,"price":148.06,"value":37015.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.99 to $148.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165007,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750401,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":600,"price":147.09,"value":88254.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.84 to $147.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165257,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750400,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":700,"price":144.61,"value":101227.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.14 to $145.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165857,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750399,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":859,"price":143.35,"value":123137.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.04 to $143.69 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":166557,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750398,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":634,"price":142.45,"value":90313.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.00 to $142.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":167416,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750397,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":690,"price":141.48,"value":97621.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.99 to $141.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":168050,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750396,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":700,"price":140.14,"value":98098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.77 to $140.64 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":168740,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750395,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":2638,"price":138.94,"value":366523.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.48 to $139.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169440,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750394,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":2329,"price":137.92,"value":321215.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.45 to $138.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":172078,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750393,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":10000,"price":13.67,"value":136700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":174407,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750392,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":664,"price":156.2,"value":103716.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.68 to $156.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164407,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750391,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":2210,"price":155.08,"value":342726.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.53 to $155.52 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165071,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750390,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":676,"price":154.07,"value":104151.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.51 to $154.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":167281,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750389,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":1995,"price":152.75,"value":304736.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.50 to $153.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":167957,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750388,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":3655,"price":152.04,"value":555706.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.50 to $152.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169952,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750387,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":800,"price":150.99,"value":120792.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.45 to $151.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":173607,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750386,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":true,"shares":1486,"price":13.67,"value":20313.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":174407,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750385,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":true,"shares":8514,"price":3.648,"value":31059.072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":172921,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3750384,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-11-28T22:08:25.000Z","date":"2018-11-26","kind":"exercise","acquired":true,"shares":29000,"price":1.184,"value":34336.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":164407,"source":{"system":"sec-edgar","filing":"0001567619-18-007046","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918007046/doc1.xml","form_type":"4"}},{"id":3796012,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":72985,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796011,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":82985,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796010,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":200,"price":165.5689,"value":33113.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.45 to $165.66 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135407,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796009,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1395,"price":164.5921,"value":229605.9795,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.29 to $165.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135607,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796008,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":2000,"price":163.6428,"value":327285.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $164.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":137002,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796007,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":3152,"price":162.6041,"value":512528.1232,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.13 to $163.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":139002,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796006,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1553,"price":161.4096,"value":250669.1088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.11 to $161.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142154,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796005,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1700,"price":160.6138,"value":273043.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.11 to $161.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143707,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796004,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-04","kind":"exercise","acquired":true,"shares":10000,"price":3.648,"value":36480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":145407,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796003,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":195,"price":169.6779,"value":33087.1905,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.60 to $169.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135407,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796002,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":3705,"price":169.003,"value":626156.115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.60 to $169.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135602,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796001,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":1297,"price":168.2902,"value":218272.3894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.60 to $168.58 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":139307,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3796000,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":673,"price":167.0908,"value":112452.1084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.54 to $167.47 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":140604,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3795999,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":1225,"price":165.9477,"value":203285.9325,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.54 to $166.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":141277,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3795998,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2001-10-03","kind":"sale","acquired":false,"shares":2905,"price":165.0058,"value":479341.849,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.50 to $165.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":142502,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3795997,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-05T20:42:25.000Z","date":"2001-10-03","kind":"exercise","acquired":true,"shares":10000,"price":3.648,"value":36480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":145407,"source":{"system":"sec-edgar","filing":"0001567619-18-003758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918003758/doc1.xml","form_type":"4"}},{"id":3815560,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"exercise","acquired":false,"shares":2527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":92985,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":2527},"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815559,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"exercise","acquired":false,"shares":7473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The options have fully vested and are immediately exercisable."}],"balance_after":56459,"derivative":{"exercise_price":1.184,"expiration_date":"2023-11-14","underlying":"Common Stock","underlying_shares":7473},"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815558,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The options have fully vested and are immediately exercisable."}],"balance_after":63932,"derivative":{"exercise_price":1.184,"expiration_date":"2023-11-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815557,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":962,"price":167.3169,"value":160958.8578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.18 to $168.1799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135407,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815556,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":3402,"price":166.523,"value":566511.246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":136369,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815555,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":5636,"price":165.425,"value":932335.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.02 to $166.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":139771,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815554,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"exercise","acquired":true,"shares":2527,"price":3.648,"value":9218.496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":145407,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815553,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-13","kind":"exercise","acquired":true,"shares":7473,"price":1.184,"value":8848.032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":142880,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815552,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":400,"price":171.075,"value":68430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.68 to $171.6799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135407,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815551,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":200,"price":169.8872,"value":33977.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.48 to $170.4799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135807,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815550,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":800,"price":168.5125,"value":134810.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.06 to $169.0599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":136007,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815549,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":1800,"price":167.3814,"value":301286.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.04 to $168.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":136807,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815548,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":2400,"price":166.4875,"value":399570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":138607,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815547,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":3700,"price":165.1821,"value":611173.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.75 to $165.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":141007,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815546,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":700,"price":164.1594,"value":114911.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.75 to $164.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":144707,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}},{"id":3815545,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":40911,"kind":"person","name":"Bilenker Joshua H.","position":1,"cik":"0001612312","reported_name":"Bilenker Joshua H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-09-14T22:17:15.000Z","date":"2018-09-12","kind":"exercise","acquired":true,"shares":10000,"price":1.184,"value":11840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":145407,"source":{"system":"sec-edgar","filing":"0001567619-18-002677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612312/000156761918002677/doc1.xml","form_type":"4"}}],"next_cursor":"2018-09-14T22:17:15.000000Z,3815545"}